Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STA363 in chronic discogenic low back pain
NCT03055845Phase 1Completed
- Sponsor
- Stayble Therapeutics
- Start
- Mar 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lactic acid in discogenic low back pain (DLBP) (4 arms), sponsored by Stayble Therapeutics. Primary endpoints: Local injection site reactions at 4 weeks, Frequency and severity of adverse events at 12 weeks and 6 more. Started Mar 2017; status: completed.
02
Drugs
lactic acid
03
Conditions
discogenic low back pain (DLBP)
Beyond the preview
Go deeper on NCT03055845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03055845.